Xanax Tapering Guide
alprazolam
Boxed Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Risks of abuse, misuse, and addiction, which can lead to overdose and death. Physical dependence and life-threatening withdrawal reactions.
Overview
Alprazolam is a short-acting, high-potency benzodiazepine approved for anxiety disorders and panic disorder. It is the most commonly prescribed benzodiazepine in the US and has the highest abuse potential among benzodiazepines due to rapid onset and short duration.
0.25mg, 0.5mg, 1mg, 2mg
Tablets: 0.25mg, 0.5mg, 1mg, 2mg; Extended-release tablets (XR): 0.5mg, 1mg, 2mg, 3mg; Orally disintegrating tablets: 0.25mg, 0.5mg, 1mg, 2mg; Oral concentrate: 1mg/mL
Category D (positive evidence of risk)
Mechanism of Action
Positive allosteric modulator at GABA-A receptors. Binds to the benzodiazepine site, enhancing GABA-mediated inhibition. Its rapid onset and short half-life contribute to both its anxiolytic efficacy and high dependence liability.
Taper Notes
Short half-life (6–12 hours) and high potency produce severe interdose withdrawal and the most challenging benzodiazepine discontinuation profile. Diazepam crossover (alprazolam 0.5 mg ≈ diazepam 10 mg) is strongly preferred over direct alprazolam taper.
Maudsley Deprescribing Guidance
Diazepam crossover is essential for most patients given short alprazolam half-life. Direct alprazolam tapers commonly fail due to interdose withdrawal. Abrupt discontinuation carries significant seizure and rebound panic risk.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Crossover to diazepam | 2-4 weeks | Strongly recommended given alprazolam's short half-life. Use Ashton equivalence: alprazolam 0.5 mg ≈ diazepam 10 mg. Stagger the substitution across daily doses. |
| Initial diazepam reductions | 2-4 weeks per step | Once stabilized on diazepam, begin ~10% proportional reductions. Diazepam's long half-life and active metabolites smooth each step. |
| Middle reductions | 3-6 months | Progressively smaller proportional reductions. Liquid diazepam (5 mg/5 mL or 5 mg/mL Intensol) supports precise sub-tablet dosing. |
| Final reductions | 3-6 months | Very gradual hyperbolic reductions. Extended hold periods (4+ weeks) per step are typically required in this phase. |
Withdrawal Timeline
6-12 hours after missed dose (fastest of all common benzos)
2-4 days (acute withdrawal can be medically dangerous)
2-4 weeks for acute symptoms if tapered properly
Rebound panic, cognitive impairment, agoraphobia, and depersonalization may persist 6-18 months. Xanax has the highest reported rate of protracted withdrawal among benzos.
Clinical Pearls
Practical considerations for clinicians supervising Xanax tapers.
- 1Direct alprazolam tapers commonly fail due to interdose withdrawal; diazepam crossover (Ashton/Maudsley protocol) is the preferred strategy for most chronic users.
- 2When direct tapering is necessary, the XR formulation provides a smoother plasma curve than IR and reduces interdose fluctuations.
- 3Rebound panic during alprazolam reduction is common and clinically indistinguishable from the underlying disorder; reassure that it is time-limited and reflects GABA-A subunit reconfiguration.
- 4Counsel patients against self-adjusting alprazolam dose; instability in dosing increases seizure risk and complicates the taper trajectory.
- 5Daily symptom tracking is essential for pace adjustment, particularly given the high frequency of windows-and-waves patterns in alprazolam discontinuation.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Opioids — FDA boxed warning: concurrent use increases risk of profound sedation, respiratory depression, coma, and death
- CYP3A4 inhibitors (ketoconazole, itraconazole, nefazodone, fluvoxamine) significantly increase alprazolam levels
- CYP3A4 inducers (carbamazepine, rifampin) decrease alprazolam levels
Food Interactions
- Food does not significantly affect absorption
- Avoid alcohol (additive CNS and respiratory depression, potentially fatal)
- Grapefruit juice increases levels via CYP3A4 inhibition
Contraindications
- Acute narrow-angle glaucoma
- Concurrent ketoconazole or itraconazole
- Known hypersensitivity to alprazolam or other benzodiazepines
Toxicity
Severe CNS and respiratory depression (especially with opioids/alcohol). Extremely high physical dependence potential. Withdrawal seizures and death possible with abrupt discontinuation. Rebound anxiety between doses.
Pharmacokinetics
ADME Profile
Rapidly absorbed after oral administration. Bioavailability ~80–90%. Tmax 1–2 hours (IR), ~11 hours (XR). Food does not significantly affect total absorption.
~0.9–1.2 L/kg
Hepatic via CYP3A4 (primary) to alpha-hydroxyalprazolam (weakly active) and a benzophenone derivative (inactive).
Renal (~80% as metabolites). Less than 20% excreted unchanged in urine.
~80%
~1.0–1.3 mL/min/kg
Build Xanax taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds